We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+4.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.7B
AUM Growth
-$252M
(-13%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-9.43%
Top 10 Holdings %
Top 10 Hldgs %
40.6%
Holding
107
New
9
Increased
39
Reduced
24
Closed
6
Top Buys
| 1 |
MMED
MiniMed Group Inc
MMED
|
+$17.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$15M |
| 3 |
Boston Scientific
BSX
|
+$9.3M |
| 4 |
HTFL
Heartflow Inc
HTFL
|
+$8M |
| 5 |
PTC Therapeutics
PTCT
|
+$7.08M |
Top Sells
| 1 |
EXAS
Exact Sciences
EXAS
|
+$61.1M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$45.3M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$27.4M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$24M |
| 5 |
Travere Therapeutics
TVTX
|
+$21.9M |
Sector Composition
| 1 | Healthcare | 99.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLNO
51
DELISTED
Soleno Therapeutics
SLNO
| $8.61M | 0.51% |
257,253
+10,200
| +4% | +$400K |
|
|
MBX
52
MBX Biosciences
MBX
$2.69B
| $8.6M | 0.51% |
287,967
+5,343
| +2% | +$182K |
|
53
Tango Therapeutics
TNGX
$4.83B
| $8.09M | 0.48% |
386,915
| – | – |
|
54
Regeneron Pharmaceuticals
REGN
$68.8B
| $7.8M | 0.46% |
10,100
| – | – |
|
55
Immunome
IMNM
$2.56B
| $7.6M | 0.45% |
347,666
| – | – |
|
56
Amylyx Pharmaceuticals
AMLX
$2.02B
| $6.95M | 0.41% |
499,764
| – | – |
|
|
OMDA
57
Omada Health Inc
OMDA
$1.39B
| $6.8M | 0.4% |
541,000
-199,000
| -27% | -$2.75M |
|
58
Inspire Medical Systems
INSP
$1.42B
| $6.8M | 0.4% |
131,800
+800
| +0.6% | +$56K |
|
|
APLS
59
DELISTED
Apellis Pharmaceuticals
APLS
| $6.55M | 0.39% |
162,750
+12,250
| +8% | +$264K |
|
60
Alkermes
ALKS
$8.6B
| $6.51M | 0.38% |
183,986
+44,758
| +32% | +$1.39M |
|
61
Evolent Health
EVH
$696M
| $6.1M | 0.36% |
2,675,000
| – | – |
|
62
Indivior Pharmaceuticals
INDV
$4.76B
| $6.1M | 0.36% |
200,000
+94,900
| +90% | +$3.13M |
|
|
TERN
63
DELISTED
Terns Pharmaceuticals
TERN
| $6M | 0.35% |
113,748
+5,267
| +5% | +$216K |
|
|
FOCL
64
EDAP TMS S.A.
FOCL
$203M
| $5.13M | 0.3% |
1,378,000
+91,500
| +7% | +$377K |
|
65
Janux Therapeutics
JANX
$962M
| $5.1M | 0.3% |
367,009
+8,211
| +2% | +$113K |
|
66
Phreesia
PHR
$664M
| $5.03M | 0.3% |
600,400
-276,200
| -32% | -$3.65M |
|
67
Thermo Fisher Scientific
TMO
$198B
| $4.92M | 0.29% |
10,000
| – | – |
|
68
Stryker
SYK
$119B
| $4.86M | 0.29% |
+14,800
| New | +$5.31M |
|
|
SION
69
Sionna Therapeutics
SION
$1.92B
| $3.99M | 0.23% |
99,429
| – | – |
|
70
Arcus Biosciences
RCUS
$3.56B
| $3.89M | 0.23% |
180,000
| – | – |
|
|
71
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| $3.83M | 0.23% |
30,000
-192,000
| -86% | -$24M |
|
72
Alphatec Holdings
ATEC
$1.38B
| $3.81M | 0.22% |
350,000
+47,500
| +16% | +$691K |
|
73
Vaxcyte
PCVX
$8.12B
| $3.5M | 0.21% |
60,250
+13,250
| +28% | +$719K |
|
74
EyePoint Inc
EYPT
$1.15B
| $3.34M | 0.2% |
258,739
| – | – |
|
|
NVO
75
Novo Nordisk
NVO
$217B
| $3.31M | 0.19% |
+90,000
| New | +$4.26M |
|
Similar funds
AAM
SGI
WAS
SI
PP
SWM
AAA
FDP